<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NATACYN- natamycin suspension </strong><br>Alcon Laboratories, Inc.<br></p></div>
<h1>
<span class="Bold">Natacyn®</span><br><span class="Bold">(natamycin ophthalmic suspension) 5%</span><br><span class="Bold">Sterile</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-1"></a><p></p>
<h1>
DESCRIPTION:
</h1>
<p class="First">NATACYN® (natamycin ophthalmic suspension) 5% is a sterile, antifungal drug for topical ophthalmic administration. Each mL of the suspension contains: <span class="Bold">Active: </span>natamycin 5% (50 mg). <span class="Bold">Preservative: </span>benzalkonium chloride 0.02%. <span class="Bold">Inactive: </span>sodium hydroxide and/or hydrochloric acid (neutralized to adjust the pH), purified water.</p>
<p>The active ingredient is represented by the chemical structure:</p>
<p>Established name: Natamycin</p>
<div class="Figure"><img alt="
chemical
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d262661c-860d-482e-aa8d-3cf1f252b32a&amp;name=chemical.jpg"></div>
<p>Molecular Formula: C<span class="Sub">33</span>H<span class="Sub">47</span>NO<span class="Sub">13</span></p>
<p>Molecular Weight: 665.73</p>
<p>Chemical name: Stereoisomer of 22-[(3-amino-3,6-dideoxy- β-D-mannopyranosyl)oxy]-1,3,26- trihydroxy-12- methyl-10-oxo-6,11,28- trioxatricyclo[22.3.1.05,7] octacosa-8,14,16,18,20-pentaene-25- carboxylic acid.</p>
<p>Other: Pimaricin</p>
<p>The pH range is 5.0 - 7.5.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-2"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY:
</h1>
<p class="First">Natamycin is a tetraene polyene antibiotic derived from <span class="Italics">Streptomyces natalensis</span>. It possesses <span class="Italics">in vitro </span>activity against a variety of yeast and filamentous fungi, including <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span>, Aspergillus, Cephalosporium, Fusarium </span>and <span class="Italics">Penicillium</span>. The mechanism of action appears to be through binding of the molecule to the sterol moiety of the fungal cell membrane. The polyenesterol complex alters the permeability of the membrane to produce depletion of essential cellular constituents. Although the activity against fungi is dose-related, natamycin is predominantly fungicidal. Natamycin is not effective <span class="Italics">in vitro </span>against gram-positive or gram-negative bacteria. Topical administration appears to produce effective concentrations of natamycin within the corneal stroma but not in intraocular fluid. Systemic absorption should not be expected following topical administration of NATACYN® (natamycin ophthalmic suspension) 5%. As with other polyene antibiotics, absorption from the gastrointestinal tract is very poor. Studies in rabbits receiving topical natamycin revealed no measurable compound in the aqueous humor or sera, but the sensitivity of the measurement was no greater than 2 mg/mL.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-3"></a><p></p>
<h1>
INDICATIONS AND USAGE:
</h1>
<p class="First">NATACYN® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, and <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> caused by susceptible organisms including <span class="Italics">Fusarium solani </span><span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>. As in other forms of suppurative <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, initial and sustained therapy of fungal <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the <span class="Italics">in vitro </span>activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span> has not been established.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-4"></a><p></p>
<h1>
CONTRAINDICATIONS:
</h1>
<p class="First">NATACYN® (natamycin ophthalmic suspension) 5% is contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="splSectionPrecautionsGeneral"></a><a name="section-5"></a><p></p>
<h1>
PRECAUTIONS: General.
</h1>
<p class="First">FOR TOPICAL OPHTHALMIC USE ONLY — NOT FOR INJECTION. Failure of improvement of <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> following 7-10 days of administration of the drug suggests that the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may be caused by a microorganism not susceptible to natamycin.</p>
<p>Continuation of therapy should be based on clinical re-evaluation and additional laboratory studies.</p>
<p>Adherence of the suspension to areas of epithelial ulceration or retention of the suspension in the fornices occurs regularly. Use only if the container is undamaged.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPrecautionsPatientInfo"></a><a name="section-6"></a><p></p>
<h1>
Information for Patients:
</h1>
<p class="First">Do not touch dropper tip to any surface, as this may contaminate the suspension. Patients should be advised not to wear contact lenses if they have signs and symptoms of fungal <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, and <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPrecautionsCarcinogen"></a><a name="section-7"></a><p></p>
<h1>
Carcinogenesis, Mutagenesis, Impairment of Fertility:
</h1>
<p class="First">There have been no long term studies done using natamycin in animals to evaluate carcinogenesis, mutagenesis, or impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-8"></a><p></p>
<h1>
Pregnancy:
</h1>
<p class="First">Pregnancy Category C. Animal reproduction studies have not been conducted with natamycin. It is also not known whether natamycin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. NATACYN® (natamycin ophthalmic suspension) 5% should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-9"></a><p></p>
<h1>
Nursing Mothers:
</h1>
<p class="First">It is not known whether these drugs are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when natamycin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-10"></a><p></p>
<h1>
Pediatric Use:
</h1>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPrecautionsGeriatric"></a><a name="section-11"></a><p></p>
<h1>
Geriatric Use:
</h1>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-12"></a><p></p>
<h1>
ADVERSE REACTIONS:
</h1>
<p class="First">The following events have been identified during post-marketing use of NATACYN® in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to their seriousness, frequency of reporting, possible causal connection to NATACYN®, or a combination of these factors include:  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, change in vision, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="378752" conceptname="Corneal opacity">corneal opacity</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, eye <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, eye <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, eye <span class="product-label-link" type="condition" conceptid="4146766" conceptname="Hyperemia">hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, foreign body sensation, parethesia, and tearing.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-13"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION:
</h1>
<p class="First">SHAKE WELL BEFORE USING. The preferred initial dosage in fungal <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> is one drop of NATACYN® (natamycin ophthalmic suspension) 5% instilled in the conjunctival sac at hourly or two-hourly intervals. The frequency of application can usually be reduced to one drop 6 to 8 times daily after the first 3 to 4 days. Therapy should generally be continued for 14 to 21 days or until there is resolution of active fungal <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>. In many cases, it may be helpful to reduce the dosage gradually at 4 to 7 day intervals to assure that the replicating organism has been eliminated. Less frequent initial dosage (4 to 6 daily applications) may be sufficient in fungal <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span> and <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-14"></a><p></p>
<h1>
HOW SUPPLIED:
</h1>
<p class="First">NATACYN® (natamycin ophthalmic suspension 5%) is a 15mL fill packaged in a 15mL amber glass bottle with a black phenolic closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately in a clear plastic <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> with Tyvek backing.</p>
<p><span class="Bold">NDC </span>0065-0645-15</p>
<p><span class="Bold">STORAGE: </span>Store between 2-24°C (36-75°F). <span class="Italics">Do not freeze</span>. Avoid exposure to light and excessive heat.</p>
<p><span class="Bold">Rx Only</span></p>
<p>©2000, 2007, 2009 Alcon, Inc.</p>
<p>Revised: May 2009</p>
<p><span class="Bold">9004669-0509</span></p>
<p><span class="Bold">ALCON LABORATORIES, INC.</span></p>
<p>6201 South Freeway</p>
<p>Fort Worth, Texas 76134 USA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-15"></a><p></p>
<h1>
PRINCIPAL DISPLAY PANEL
</h1>
<p class="First">NDC 0065-0645-15</p>
<p>Alcon®</p>
<p>Natacyn®</p>
<p>(natamycin ophthalmic suspension) 5%</p>
<p>Anti-Fungal Ophthalmic Suspension</p>
<p>Rx Only</p>
<p>5 mL                                    Sterile</p>
<div class="Figure"><img alt="
carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d262661c-860d-482e-aa8d-3cf1f252b32a&amp;name=carton.jpg"></div>
<div class="Figure"><img alt="
label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d262661c-860d-482e-aa8d-3cf1f252b32a&amp;name=label.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NATACYN 		
					</strong><br><span class="contentTableReg">natamycin suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0065-0645</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NATAMYCIN</strong> (NATAMYCIN) </td>
<td class="formItem">NATAMYCIN</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0065-0645-15</td>
<td class="formItem">15 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050514</td>
<td class="formItem">12/31/1980</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alcon Laboratories, Inc.
							(008018525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Alcon Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">008018525</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b703806d-0139-42aa-a8ea-8dd3e9470a98</div>
<div>Set id: d262661c-860d-482e-aa8d-3cf1f252b32a</div>
<div>Version: 2</div>
<div>Effective Time: 20110713</div>
</div>
</div> <div class="DistributorName">Alcon Laboratories, Inc.</div></p>
</body></html>
